← Search & browse all drugs
VARIOUS › DIAGNOSTIC AGENTS › OTHER DIAGNOSTIC AGENTS › Tests for fertility disturbances
gonadorelin
V04CM01
Forms & Strengths
- Injectable powder for reconstitution: 100 mcg, 1 mg per vial
- Diagnostic injection solution: various strengths
Adult Dosing
- Diagnostic test for hypothalamic-pituitary gonadotropic function: 100 mcg IV or SC administered as a single injection
- Evaluation of delayed puberty: 100 mcg IV single dose
Pediatric Dosing
- Diagnostic evaluation of prepubertal and pubertal delay: 1 mcg/kg (up to 100 mcg) IV or SC as a single dose
- Safety and efficacy in neonates and infants not established
Indications
- Evaluation of primary versus secondary amenorrhea
- Assessment of hypothalamic-pituitary gonadotropic function
- Evaluation of delayed puberty in adolescents
Mechanism of Action
- Synthetic decapeptide identical to naturally occurring gonadotropin-releasing hormone (GnRH)
- Binds to gonadotroph receptors in the anterior pituitary gland
- Stimulates the synthesis and release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
Contraindications
- Hypersensitivity to gonadorelin or any component of the formulation
- Sex hormone-dependent tumors (e.g., carcinoma of the prostate or breast)
- Pregnancy (Category X)
Adverse Reactions
- Headache
- Nausea
- Lightheadedness
- Abdominal pain
- Flushing
- Local injection site reactions (pain, swelling, redness)
Drug Interactions
- Androgens, estrogens, and progestins may alter pituitary responsiveness to gonadorelin
- Digoxin may decrease pituitary response
- Dopamine antagonists and levodopa may increase gonadotropin response
- Glucocorticoids may suppress the pituitary response to gonadorelin
Curated Content: Needs Vetting Before Put to Clinical Use